Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.70 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.70 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.57 |
| ▸ | ST6GAL1 | P15907 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026416 | 0.92 | LMNA (0.72) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL28403435 | 0.92 | LMNA (0.72) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL338709 | 0.91 | LMNA (0.70) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5491562 | 0.87 | LMNA (0.75) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL366600 | 0.87 | LMNA (0.75) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4946508 | 0.87 | LMNA (0.75) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL27364585 | 0.86 | LMNA (0.61) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17304691 | 0.86 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2811458 | 0.86 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL13524621 | 0.86 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994014981-A1 | TREATMENT OF VIRAL INFECTIONS | CHEN ROLLAND (US) | 1994-07-07 | — | — | WO | claimed |
| JP-9107965-A | — | — | None | — | — | JP | disclosed |
| US-20240226188-A9 | COMPOSITIONS COMPRISING ANIMAL HEMOGLOBIN | EVELO BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-114630911-B | Enzymatic process for the preparation of UDP-GlcNAc | 马克斯·普朗克科学促进学会 | 2024-06-28 | — | — | CN | disclosed |
| US-20240131083-A1 | COMPOSITIONS COMPRISING ANIMAL HEMOGLOBIN | EVELO BIOSCIENCES INC (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117120060-A | Aqueous solutions containing purines and pyrimidines and use thereof | 周格尼克斯-莫迪斯公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230340116-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM CELLS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-10-26 | — | — | US | disclosed |
| CN-114641577-B | Enzymatic process for the preparation of UDP-galactose | 马克斯·普朗克科学促进学会 | 2023-06-23 | — | — | CN | disclosed |
| CN-113748212-B | Enzymatic process for preparing GDP-fucose | 马克斯·普朗克科学促进学会 | 2023-04-25 | — | — | CN | disclosed |
| US-20230090600-A1 | MICROBIAL FERMENTATION FOR THE PRODUCTION OF ISOPRENOID ALCOHOLS AND DERIVATIVES | LANZATECH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-6774082-B2 | COMPOSITION FOR USE IN THE SEPARATION OF PREFERENTIAL BIOPOLYMERS FROM SAMPLE | IBC ADVANCED TECHNOLOGIES, INC. | 2004-08-10 | — | — | US | disclosed |
| WO-2004035614-A1 | SYNTHETIC OR PARTIALLY PURIFIED PEPTIDES WHICH CAN BIND TO SPECIFIC SUBUNITS OF G PROTEINS AND USES THEREOF | KARO BIO AB (SE) | 2004-04-29 | — | — | WO | disclosed |
| US-20030050458-A1 | Compositions and methods for separating heterocyclic aromatic amine bases, nucleosides, nucleotides, and nucleotide sequences | IBC ADVANCED TECHNOLOGIES, INC. | 2003-03-13 | — | — | US | disclosed |
| EP-1290004-A1 | METHOD OF IDENTIFYING CRITICAL POINTS WITHIN PROTEIN-PROTEIN INTERACTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002092766-A2 | COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES | IBC ADVANCED TECHNOLOGIES, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| US-6365359-B1 | IDENTIFYING PRP PHARMACORE BY DETERMINING FUNCTIONAL RESIDUES OF PROTEIN INVOLVED IN COMPLEX INTERACTIONS, DEVELOPING THREE DIMENSIONAL STRUCTURES, COMPARING THEM WITH OTHER COMPOUNDS AND IDENTIFYING COMPOUNDS CONSISTENT WITH BINDING TO PROTEIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-02 | — | — | US | disclosed |
| WO-2001087911-A1 | METHOD OF IDENTIFYING CRITICAL POINTS WITHIN PROTEIN-PROTEIN INTERACTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-22 | — | — | WO | disclosed |
| US-20010023067-A1 | Nucleic acid molecules encoding polypeptides having the enzymatic activity of an RNA-directed RNA polymerase (RdRP) | MICHAEL WASSENEGGER AND LEONHARD RIEDEL | 2001-09-20 | — | — | US | disclosed |
| US-6218142-B1 | NUCLEOTIDE AND AMINO ACID SEQUENCE; RECOMBINANT CULTURE PRODUCTION; ANTIBODIES; ANTAGONISTS; TRANSGENIC PLANT CELLS; DIAGNOSIS; KITS | Wassenegger, Michael (DE) | 2001-04-17 | — | — | US | disclosed |
| JP-H09107965-A | PRODUCTION OF ACYLNOYLAMINATE CYTIDYLYL TRANSFERASE | KOHJIN CO LTD | 1997-04-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050458-A1 | Compositions and methods for separating heterocyclic aromatic amine bases, nucleosides, nucleotides, and nucleotide sequences | NUDT1, ATIC, PNP | LMNA 1739/4885THRB 4461/4885MTOR 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.